Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Viral Hepatitis Studies Influencing My Practice Following AASLD 2021

Source: Clinical Impact of New Viral Hepatitis Data From AASLD 2021*
November 12-15, 2021; Virtual
Listen to expert insights from Nancy Reau, MD, on updates and new viral hepatitis data from AASLD 2021, including HBV treatment in pregnancy, outcomes following HBV treatment withdrawal, progress toward HBV cure, HCV implementation science and the cascade of care, characterization of the population with hepatitis delta, and phase III clinical trial updates for hepatitis delta.
Nancy Reau, MD
Released: December 1, 2021

In this episode, Nancy Reau, MD, discusses new viral hepatitis data from AASLD 2021, including:

  • HBV treatment in pregnancy
  • Outcomes following HBV treatment withdrawal  
  • Progress toward an HBV cure
  • HCV implementation science and current status of the cascade of care
  • Hepatitis delta virus: understanding the clinical impact
  • Phase III clinical trial updates for hepatitis delta virus, including data on bulevirtide

Information on this Educational Activity

Faculty

Nancy Reau, MD

Professor of Medicine
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Richard B. Capps Chair of Hepatology
Rush University Medical Center
Chicago, Illinois

Nancy Reau, MD, has disclosed that she has received funds for research support paid to her institution from AbbVie and Gilead Sciences and consulting fees from AbbVie, Arbutus, Gilead Sciences, Intercept, and Salix.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
Gilead Sciences, Inc.

Related Content

Dr Paul Kwo discusses evolving treatment options for hepatitis delta virus (HDV), from Clinical Care Options (CCO)

Paul Y. Kwo, MD Released: August 2, 2022

Download slides reviewing the latest data and guidance on approaches to managing patients with hepatitis delta virus (HDV), from Clinical Care Options (CCO)

person default Joseph (Patient) Maria Buti, MD person default Richard H. Davis, PA-C Robert G. Gish, MD Nancy Reau, MD Stefan Zeuzem, MD Released: July 25, 2022

Dr Nancy Reau on exciting viral hepatitis data from EASL 2022, including HBV, HDV (hepatitis delta), and HCV, from Clinical Care Options (CCO)

Nancy Reau, MD Released: July 13, 2022

Clinical Care Options (CCO) expert analysis by Prof Tarik Asselah on new viral hepatitis data from EASL 2022, including HBV, HDV, and HCV

Tarik Asselah, MD, PhD Released: July 8, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings